Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of GW906 (SAL0132) Injection in Patients With Essential Hypertension

NCT07835971 is registered in ClinicalTrials.gov with Shenzhen Salubris Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT07835971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07835971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of GW906 (SAL0132) Injection in Patients With Essential Hypertension
Lead sponsor
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 24, 2025
Completion date
September 15, 2026
Enrollment
319 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension